ICIs that target PD-1 (ex: pembrolizumab, nivolumab, camrelizumab), PD-L1 (ex: atezolizumab, avelumab, durvalumab), and CTLA-4 molecules (ex: ipilimumab, tremelimumab) have shown to have clinical benefit including long-term remissions and OS of CRC patients. The gene discussed is CTLA4; the disease is colorectal carcinoma.